Axsome Therapeutics, Inc.NASDAQ: AXSM

Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

· Issued by Axsome Therapeutics, Inc.

On 6ix: 6ix.com/news/axsome-therapeutics-enters-into-exclusive-license-agreement-with-pfizer-inc-for-pfizers-reboxetine-clinical-and-nonclinical-data-and-for-new-phase-3-esreboxetine-product-candidate

Watch Axsome Therapeutics' latest callAxsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings Call · Replay · Aug 10Read the transcript of Axsome Therapeutics (NASDAQ:AXSM) Q2 2026 Earnings Call
Axsome Therapeutics' next earnings callAxsome Therapeutics (NASDAQ:AXSM) Q3 2026 Earnings Call · Nov 2, 2026 at 8:00 AM ESTRegister

Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy

Expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia

Esreboxetine met primary endpoints in completed Pfizer Phase 3 and Phase 2 placebo-controlled clinical trials in fibromyalgia (p

Axsome Therapeutics, Inc. on 6ix

In the deck

Earlier from Axsome Therapeutics

Later from Axsome Therapeutics

All Axsome Therapeutics news releases